| Title: |
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial |
| Authors: |
Brown, Samuel M; Barkauskas, Christina E; Grund, Birgit; Sharma, Shweta; Phillips, Andrew N; Leither, Lindsay; Peltan, Ithan D; Lanspa, Michael; Gilstrap, Daniel L; Mourad, Ahmad; Lane, Kathleen; Beitler, Jeremy R; Serra, Alexis L; Garcia, Ivan; Almasri, Eyad; Fayed, Mohamed; Hubel, Kinsley; Harris, Estelle S; Middleton, Elizabeth A; Barrios, Macy AG; Mathews, Kusum S; Goel, Neha N; Acquah, Samuel; Mosier, Jarrod; Hypes, Cameron; Salvagio Campbell, Elizabeth; Khan, Akram; Hough, Catherine L; Wilson, Jennifer G; Levitt, Joseph E; Duggal, Abhijit; Dugar, Siddharth; Goodwin, Andrew J; Terry, Charles; Chen, Peter; Torbati, Sam; Iyer, Nithya; Sandkovsky, Uriel S; Johnson, Nicholas J; Robinson, Bryce RH; Matthay, Michael A; Aggarwal, Neil R; Douglas, Ivor S; Casey, Jonathan D; Hache-Marliere, Manuel; Georges Youssef, J; Nkemdirim, William; Leshnower, Brad; Awan, Omar; Pannu, Sonal; O'Mahony, Darragh Shane; Manian, Prasad; Awori Hayanga, JW; Wortmann, Glenn W; Tomazini, Bruno M; Miller, Robert F; Jensen, Jens-Ulrik; Murray, Daniel D; Bickell, Nina A; Zatakia, Jigna; Burris, Sarah; Higgs, Elizabeth S; Natarajan, Ven; Dewar, Robin L; Schechner, Adam; Kang, Nayon; Arenas-Pinto, Alejandro; Hudson, Fleur; Ginde, Adit A; Self, Wesley H; Rogers, Angela J; Oldmixon, Cathryn F; Morin, Haley; Sanchez, Adriana; Weintrob, Amy C; Cavalcanti, Alexandre Biasi; Davis-Karim, Anne; Engen, Nicole; Denning, Eileen; Taylor Thompson, B; Gelijns, Annetine C; Kan, Virginia; Davey, Victoria J; Lundgren, Jens D; Babiker, Abdel G; Neaton, James D; Lane, H Clifford; ACTIV-3b/Therapeutics for Severely Ill Inpatients with COVID-19 |
| Source: |
The Lancet Respiratory Medicine , 11 (9) pp. 791-803. (2023) |
| Publisher Information: |
Elsevier |
| Publication Year: |
2023 |
| Collection: |
University College London: UCL Discovery |
| Subject Terms: |
ACTIV-3b/Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Study Group |
| Description: |
BACKGROUND: There is a clinical need for therapeutics for COVID-19 patients with acute hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-protective neuropeptide, and remdesivir, a nucleotide prodrug of an adenosine analog, were compared with placebo among patients with COVID-19 acute hypoxaemic respiratory failure. METHODS: TESICO was a randomised trial of aviptadil and remdesivir versus placebo at 28 sites in the USA. Hospitalised adult patients were eligible for the study if they had acute hypoxaemic respiratory failure due to confirmed SARS-CoV-2 infection and were within 4 days of the onset of respiratory failure. Participants could be randomly assigned to both study treatments in a 2 × 2 factorial design or to just one of the agents. Participants were randomly assigned with a web-based application. For each site, randomisation was stratified by disease severity (high-flow nasal oxygen or non-invasive ventilation vs invasive mechanical ventilation or extracorporeal membrane oxygenation [ECMO]), and four strata were defined by remdesivir and aviptadil eligibility, as follows: (1) eligible for randomisation to aviptadil and remdesivir in the 2 × 2 factorial design; participants were equally randomly assigned (1:1:1:1) to intravenous aviptadil plus remdesivir, aviptadil plus remdesivir matched placebo, aviptadil matched placebo plus remdesvir, or aviptadil placebo plus remdesivir placebo; (2) eligible for randomisation to aviptadil only because remdesivir was started before randomisation; (3) eligible for randomisation to aviptadil only because remdesivir was contraindicated; and (4) eligible for randomisation to remdesivir only because aviptadil was contraindicated. For participants in strata 2-4, randomisation was 1:1 to the active agent or matched placebo. Aviptadil was administered as a daily 12-h infusion for 3 days, targeting 600 pmol/kg on infusion day 1, 1200 pmol/kg on day 2, and 1800 pmol/kg on day 3. Remdesivir was administered as a 200 mg loading dose, ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
text |
| Language: |
English |
| Relation: |
https://discovery.ucl.ac.uk/id/eprint/10173550/1/Miller_Intravenous%20Aviptadil%20.pdf; https://discovery.ucl.ac.uk/id/eprint/10173550/ |
| Availability: |
https://discovery.ucl.ac.uk/id/eprint/10173550/1/Miller_Intravenous%20Aviptadil%20.pdf; https://discovery.ucl.ac.uk/id/eprint/10173550/ |
| Rights: |
open |
| Accession Number: |
edsbas.4EA8215E |
| Database: |
BASE |